Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 20, 1999

Last Updated Date

June 23, 2005

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Drug use
Effectiveness of medication
Level of pharm
Retention
Depression, anxiety

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00000217 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

Official Title ^ICMJE

Pharmacotherapy and Intensive Treatment of Drug Abuse

Brief Summary

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Detailed Description

Study Phase

Phase II

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment

Condition ^ICMJE

Cocaine-Related Disorders
Substance-Related Disorders

Intervention ^ICMJE

Drug: Carbamazepine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Please contact site for information.

Gender

Both

Ages

18 Years to 60 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00000217

Responsible Party

Study ID Numbers ^ICMJE

NIDA-06954-1, R18-06954-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

Department of Veterans Affairs

Investigators ^ICMJE

Principal Investigator:

William Haning, M.D.

University of Kansas

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

December 2002

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP